News

CDC accepts RSV recommendations made by former vaccine panel
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
Verywell Health on MSN1d
Not Enough Adults Are Getting the RSV Vaccine. Here's Why That Matters
Fact checked by Nick Blackmer The Centers for Disease Control and Prevention (CDC) has expanded the RSV vaccine ...
Zacks Investment Research on MSN13d
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
Kennedy Expands RSV Vaccine Recommendations. Moderna, Pfizer Shares Are Up.
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...
RSV vaccine access expanded to some people in their 50s, according to CDC website
The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...
BioSpace13d
Kennedy Follows RSV Recommendations of ACIP Members He Fired
Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...
HealthDay on MSN9d
CDC Now Recommends RSV Vaccine for Some Adults 50+
Key Takeaways High-risk adults as young as 50 are now eligible for the RSV vaccineThe update follows advice from now-deposed ...
Stocktwits on MSN13d
CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panel
The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...
Zacks Investment Research on MSN2d
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...
Pharmaceutical Technology on MSN2d
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
AllAfrica on MSN1d
Government Is Considering Providing a Vaccine to Protect Babies From RSV
A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...